$6.14
4.60% today
NYSE, Aug 22, 10:00 pm CET
ISIN
US29384C1080
Symbol
TRDA

Entrada Therapeutics Stock price

$6.14
-0.24 3.76% 1M
-6.71 52.22% 6M
-11.15 64.49% YTD
-9.97 61.89% 1Y
-6.98 53.20% 3Y
-17.81 74.36% 5Y
-17.81 74.36% 10Y
-17.81 74.36% 20Y
NYSE, Closing price Fri, Aug 22 2025
+0.27 4.60%
ISIN
US29384C1080
Symbol
TRDA
Industry

Key metrics

Basic
Market capitalization
$223.3m
Enterprise Value
$-130.7m
Net debt
positive
Cash
$354.0m
Shares outstanding
38.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
2.8 | 4.7
EV/Sales
negative | negative
EV/FCF
1.0
P/B
0.6
Financial Health
Equity Ratio
81.5%
Return on Equity
15.3%
ROCE
-22.4%
ROIC
-99.5%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$79.5m | $47.7m
EBITDA
$-92.3m | $-137.8m
EBIT
$-96.2m | $-145.5m
Net Income
$-73.4m | $-122.7m
Free Cash Flow
$-126.6m
Growth (TTM | estimate)
Revenue
-66.8% | -77.4%
EBITDA
-195.3% | -371.3%
EBIT
-202.9% | -409.5%
Net Income
-170.2% | -286.9%
Free Cash Flow
-584.9%
Margin (TTM | estimate)
Gross
-
EBITDA
-116.1% | -288.7%
EBIT
-121.0%
Net
-92.3% | -257.1%
Free Cash Flow
-159.2%
More
EPS
$-1.8
FCF per Share
$-3.3
Short interest
5.6%
Employees
183
Rev per Employee
$1.2m
Show more

Is Entrada Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Entrada Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Entrada Therapeutics forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Entrada Therapeutics forecast:

Buy
90%
Hold
10%

Financial data from Entrada Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
79 79
67% 67%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 41 41
18% 18%
52%
- Research and Development Expense 135 135
21% 21%
169%
-92 -92
195% 195%
-116%
- Depreciation and Amortization 3.91 3.91
15% 15%
5%
EBIT (Operating Income) EBIT -96 -96
203% 203%
-121%
Net Profit -73 -73
170% 170%
-92%

In millions USD.

Don't miss a Thing! We will send you all news about Entrada Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Entrada Therapeutics Stock News

Neutral
The Motley Fool
16 days ago
Entrada (TRDA) Q2 Revenue Drops 98%
Neutral
GlobeNewsWire
16 days ago
-- First patient dosed in ELEVATE-44-201 with data from first patient cohort anticipated in H1 2026 -- -- Initiated ELEVATE-45-201 and on track to dose the first patient in Q3 2025 -- -- Multiple clinical trial sites in U.K. and EU activated for ELEVATE-44-201 and ELEVATE-45-201 -- -- Leadership team expanded with the additions of Navid Khan, PhD, as Senior Vice President of Medical Affairs and...
Neutral
GlobeNewsWire
3 months ago
BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors.
More Entrada Therapeutics News

Company Profile

Entrada Therapeutics, Inc. operates as a biotechnology company. It focuses on delivery of biomolecules into the cell to treat devastating diseases. The firm offers intracellular enzyme replacement therapy and protein-protein interaction inhibitors programs. The company focuses on creating and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to target and engage underlying drivers of diseases. Entrada Therapeutics was founded by Dehua Pei in September 22, 2016 and is headquartered in Boston, MA.

Head office United States
CEO Dipal Doshi
Employees 183
Founded 2016
Website www.entradatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today